Home / Investors

Information for investors

The share

Detailed information on the current course, order depth and recent trades for PEPTONIC Medical shares is presented on our Investor Relations page on spotlightstockmarket.com.

More on the share on spotlightstockmarket.com »
Current share graph »

Financial information

Annual reports and company analysis can be found and downloaded under Financial information.

More financial information about PEPTONIC medical is available on spotlightstockmarket.com.

Contacts for investor information

Erik Sundquist

CEO Erik Sundquist

+46 722 499 043
E-mail: erik.sundquist@peptonicmedical.se


Recent Comments

    All press releases on Spotlightstockmarket.com

    All published press releases from PEPTONIC medical is available on spotlightstockmarket.com.

    About us

    PEPTONIC Medical is an innovative Swedish pharmaceutical company developing and commercializing safe and effective products for the treatment of menopausal symptoms, such as vaginal atrophy. VagiVital® is a registered trademark of PEPTONIC Medical. The product is being commercialised for the non-prescription use for the treatment of vaginal atrophy.

    The Company was founded in 2009 and its first candidate drug product is Vagitocin® – an estrogen-free oxytocin based product for the treatment of vaginal atrophy in clinical development phase 2.

    Oxytocin has a long history of safe and effective medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women.